Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID Sales of Investments
Cash received from selling or redeeming investments.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments growth accelerates
Q1 FY2026 sales of investments of $12.01M rose 9.1% year over year, ahead of the -34.0% change in trailing-twelve-month sales of investments. Sequentially, it rose 50.1% from the prior quarter. Over 3 fiscal years it compounded at -23.0% a year.
Context
- Sales of investments amounted to 125.8% of revenue in FY2025, down 134.6 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +9.1% holds above the trailing-twelve-month pace of -34.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 42.26M USD
- Year-over-year change
- -42.2%
- 4-year CAGR
- +29.6%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.26M | -42.2% |
| FY2024 | 2024-12-31 | 73.06M | -31.4% |
| FY2023 | 2023-12-31 | 106.49M | +15.1% |
| FY2022 | 2022-12-31 | 92.5M | +516.7% |
| FY2021 | 2021-12-31 | 15M | — |
Sales of Investments vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 sales of investments of $43.26M is the 2nd largest of the 9 companies compared; the peer median is $0.
- Its year-over-year change of -34.0% is the 3rd highest of 4, against a peer median of +18.1%.
- Sales of investments amounts to 125.8% of revenue for RPID, versus a peer median of 11.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $58.07M | +18.1% | +3.2% | 101877.2% | |
| LTM Mar 2026 | $43.26M | -34.0% | -23.0% | 125.8% | |
| LTM Mar 2026 | $22.5M | -64.3% | -20.9% | 31.1% | |
| LTM Mar 2026 | $13.75M | +28.0% | — | 23.8% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding RPID) | $0 | +18.1% | -8.8% | 11.9% | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.84M | 4.02M | 4.75M | 3.87M | 4.03M |
| Change in Working Capital | (8M) | (5.33M) | 555K | (4.77M) | 6.06M |
| Accounts Receivables | (17K) | (364K) | (163K) | (1.99M) | 4.39M |
| Inventory | (6.77M) | (5.84M) | 1.19M | (335K) | 1.47M |
| Accounts Payables | (524K) | 1.48M | (3.46M) | 562K | 1.6M |
| Other Working Capital | (691K) | (602K) | 2.98M | (3.01M) | (1.39M) |
| Other Non-Cash Items | 23.19M | 728K | (1.02M) | 271K | 2.71M |
| Operating Cash Flow | (54.96M) | (58.55M) | (45.08M) | (44.15M) | (31.06M) |
| Capital Expenditures | (3.22M) | (6.74M) | (1.85M) | (1.37M) | (850K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (25.09M) | (179.23M) | (62.49M) | (35.04M) | (27.08M) |
| Sales of Investments | 15M | 92.5M | 106.49M | 73.06M | 42.26M |
| Other Investing Activities | 20K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (13.29M) | (93.47M) | 42.15M | 36.66M | 14.33M |
| Debt Repayment | (26.17M) | (33K) | (37K) | (35K) | 19.09M |
| Common Stock Issued | 164.11M | 0 | 0 | 238K | 1.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (940K) | 726K | 186K | 0 | (419K) |
| Financing Cash Flow | 216.75M | 693K | 149K | 203K | 19.77M |
| Effect of Forex Changes | 0 | 0 | 0 | (81K) | 0 |
| Net Change in Cash | 148.49M | (151.32M) | (2.78M) | (7.37M) | 3.04M |
| Free Cash Flow | (58.18M) | (65.29M) | (46.93M) | (45.52M) | (31.91M) |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.